drugset / Trial / NCT07169994
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Timeline
- Start
- 2025-09-02
- Primary completion
- 2026-09-01
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firmonertinib | Small molecule | — | Oral |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |
| Subject | YL202 | Unknown | — | Intravenous |